IP Library Granted Patent US 6,916,918
Granted Patent B2
US 6,916,918 · App. 09/875,228 · Granted Jul 12, 2005

Human glandular kallikrein enhancer, vectors comprising the enhancer and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,916,918
App. No.
09/875,228
Granted
Jul 12, 2005
Kind
B2
Abstract

Enhancers which preferentially increase the transcription of cis-linked coding sequences in prostate cells are provided. Methods of using DNA constructs comprising the enhancers to control transcription of heterologous polynucleotides are also provided. Delivery vehicles comprising the enhancers and methods of using the vehicles are also provided. Adenovirus vectors in which one or more genes are under transcriptional control of the enhancers of the invention are also provided. Further provided are methods of using the adenovirus vectors of the invention to confer selective cytotoxicity in mammalian cells.

Claims (14)

1. An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:1, or a fragment thereof of comprising bases 8192-8206 of SEQ ID NO:1, wherein said polynucleotide or said fragment thereof has prostate-specific enhancer activity.

2. An isolated polynucleotide comprising nucleotides about 8021 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has prostate-specific enhancer activity.

3. An isolated polynucleotide according to claim 2 , wherein the polynucleotide comprises nucleotides about 7200 to about 8371 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

4. An isolated polynucleotide according to claim 2 , wherein the polynucleotide comprises nucleotides about 6859 to about 8627 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

5. An isolated polynucleotide according to claim 2 , wherein the polynucleotide comprises nucleotides about 5976 to about 9620 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

6. An isolated polynucleotide according to claim 2 , wherein the polynucleotide comprises nucleotides about 1 to about 9765 of SEQ ID NO:1, wherein said polynucleotide has enhancer activity.

7. An adenovirus vector for selective cytolysis of a prostate target cell comprising an adenovirus gene essential for replication under transcriptional control of a human glandular kallikrein transcription regulatory element (hKLK2-TRE), wherein said hKLK2-TRE comprises a promoter and nucleotides about 8021 to about 8371 of SEQ ID NO:1.

8. The adenovirus vector of claim 7 , wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

9. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 7200 to about 8371 of SEQ ID NO:1.

10. The adenovirus vector according to claim 9 , wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

11. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 6859 to about 8627 of SEQ ID NO:1.

12. The adenovirus vector according to claim 11 , wherein said adenovirus gene essential for adenoviral replication is selected from the group consisting of E1A, E1B, E2 and E4.

13. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 5976 to about 9620 of SEQ ID NO:1.

14. The adenovirus vector according to claim 7 wherein said hKLK2-TRE comprises nucleotides about 1 to about 9765 of SEQ ID NO:1.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2001
From: CALYDON, INC
To: CELL GENESYS, INC
Reel/Frame 012243/0012 →